WALTHAM, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has granted inducement equity awards to 16 newly hired employees. The awards were made as an inducement material to the newly hired employees’ acceptance of employment with Dyne in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity
Detailed price information for Dyne Therapeutics Inc (DYN-Q) from The Globe and Mail including charting and trades.
Detailed price information for Dyne Therapeutics Inc (DYN-Q) from The Globe and Mail including charting and trades.
WALTHAM, Mass., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has granted inducement equity awards to 14 newly hired employees. The awards were made as an inducement material to the newly hired employees’ acceptance of employment with Dyne in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity
Dyne Therapeutics announced it will present additional one-year clinical data from its Phase 1/2 ACHIEVE trial of zeleciment basivarsen for myotonic dystrophy type 1 at upcoming World Muscle Society and AANEM meetings in late September and early October 2026. The breadth of new functional and safety data, alongside details from a matched natural history cohort and a fully enrolled registrational expansion cohort, adds depth to Dyne’s emerging clinical story in DM1. We’ll now examine how...
Tipranks Press Release.
Dyne Therapeutics lead asset z-rostudirsen faces regulatory and confirmatory risks, with FDA approval likely. Find out why DYN stock is a buy.
Dyne Therapeutics (DYN) has an average rating of buy and mean price target of $37.27, according to a
Dyne Therapeutics (DYN) investment thesis remains intact despite a setback for Novartis (NVS) in a p
Dyne Therapeutics (DYN) has an average rating of buy and mean price target of $37.27, according to a
- Data from a pooled dose group of participants initially enrolled in the multiple ascending dose portion of the trial to be compared against a matched natural history cohort - - Dyne also intends to provide the mean baseline value for video hand opening time (vHOT) in the ACHIEVE registrational expansion cohort (REC) in conjunction with these presentations - - Topline data from the ACHIEVE REC are on track for Q1 2027 - WALTHAM, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc.
Dyne Therapeutics (NASDAQ:DYN) shares fell 31. 0% to $16.
Novartis stock sinks 13% after del-desiran phase 3 trial failed primary endpoints, sparking biotech selloff.
- Data support the ongoing development of four investigational therapies for DMD amenable to skipping of exons 53, 45, 44 or 55, all of which are advancing into IND-enabling studies - - All development candidates leverage the same FORCE™ platform as zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251), which is under FDA review for exon 51 DMD - WALTHAM, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering funct
WALTHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to participate in the following upcoming investor conferences: 2026 Cantor Global Healthcare Conference, fireside chat on Friday, September 11, 2026 at 10:20 a.m. ET in New York, NYMorgan Stanley 24th Annual Global Healthcare Con
This is the newest page. Registered accounts read further back.